Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.
2.

Randomized evaluation and cost-effectiveness of HIV and sexual and reproductive health service referral and linkage models in Zambia.

Hewett PC, Nalubamba M, Bozzani F, Digitale J, Vu L, Yam E, Nambao M.

BMC Public Health. 2016 Aug 12;16:785. doi: 10.1186/s12889-016-3450-x.

3.

Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women Above Age 30 Years.

Jin XW, Lipold L, Foucher J, Sikon A, Brainard J, Belinson J, Schramm S, Nottingham K, Hu B, Rothberg MB.

J Gen Intern Med. 2016 Nov;31(11):1338-1344. Epub 2016 Jul 14.

PMID:
27418345
4.

Cost-Effectiveness of Different Cervical Screening Strategies in Islamic Republic of Iran: A Middle-Income Country with a Low Incidence Rate of Cervical Cancer.

Nahvijou A, Daroudi R, Tahmasebi M, Amouzegar Hashemi F, Rezaei Hemami M, Akbari Sari A, Barati Marenani A, Zendehdel K.

PLoS One. 2016 Jun 8;11(6):e0156705. doi: 10.1371/journal.pone.0156705. eCollection 2016.

5.

The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation study.

Naber SK, de Kok IM, Matthijsse SM, van Ballegooijen M.

Cancer Causes Control. 2016 Apr;27(4):569-81. doi: 10.1007/s10552-016-0732-7. Epub 2016 Mar 12.

6.

Cervical Cancer Screening in Partly HPV Vaccinated Cohorts - A Cost-Effectiveness Analysis.

Naber SK, Matthijsse SM, Rozemeijer K, Penning C, de Kok IM, van Ballegooijen M.

PLoS One. 2016 Jan 29;11(1):e0145548. doi: 10.1371/journal.pone.0145548. eCollection 2016.

7.

Combining CXCL10 gene therapy and radiotherapy improved therapeutic efficacy in cervical cancer HeLa cell xenograft tumor models.

Zhao M, Ma Q, Xu J, Fu S, Chen L, Wang B, Wu J, Yang L.

Oncol Lett. 2015 Aug;10(2):768-772. Epub 2015 May 27.

8.

Cervical cancer screening among women ≥70 years of age in the United States-A referral problem or patient choice.

Guo F, Hirth JM, Berenson AB.

Prev Med. 2015 Dec;81:427-32. doi: 10.1016/j.ypmed.2015.10.005. Epub 2015 Oct 21.

9.

Return on investment: a fuller assessment of the benefits and cost savings of the US publicly funded family planning program.

Frost JJ, Sonfield A, Zolna MR, Finer LB.

Milbank Q. 2014 Dec;92(4):696-749. doi: 10.1111/1468-0009.12080. Epub 2014 Oct 15.

10.

Cervical cancer screening with AMIGAS: a cost-effectiveness analysis.

Lairson DR, Chang YC, Byrd TL, Lee Smith J, Fernandez ME, Wilson KM.

Am J Prev Med. 2014 Jun;46(6):617-23. doi: 10.1016/j.amepre.2014.01.020.

11.

Overview of the CDC Cervical Cancer (Cx3) Study: an educational intervention of HPV testing for cervical cancer screening.

Benard VB, Saraiya M, Greek A, Hawkins NA, Roland KB, Manninen D, Ekwueme DU, Miller JW, Unger ER.

J Womens Health (Larchmt). 2014 Mar;23(3):197-203. doi: 10.1089/jwh.2013.4655. Epub 2013 Dec 31.

12.

A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions.

Villanti AC, Jiang Y, Abrams DB, Pyenson BS.

PLoS One. 2013 Aug 7;8(8):e71379. doi: 10.1371/journal.pone.0071379. Print 2013.

13.

Telemedical cervical cancer screening to bridge medicaid service care gap for rural women.

Hitt WC, Low G, Bird TM, Ott R.

Telemed J E Health. 2013 May;19(5):403-8. doi: 10.1089/tmj.2012.0148.

14.

CXCL10 enhances radiotherapy effects in HeLa cells through cell cycle redistribution.

Yang LL, Wang BQ, Chen LL, Luo HQ, Wu JB.

Oncol Lett. 2012 Feb;3(2):383-386. Epub 2011 Nov 4.

15.

Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model.

de Kok IM, van Rosmalen J, Dillner J, Arbyn M, Sasieni P, Iftner T, van Ballegooijen M.

BMJ. 2012 Mar 5;344:e670. doi: 10.1136/bmj.e670.

16.

Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing.

van Rosmalen J, de Kok IM, van Ballegooijen M.

BJOG. 2012 May;119(6):699-709. doi: 10.1111/j.1471-0528.2011.03228.x. Epub 2012 Jan 18.

17.

Economic evaluation of three populational screening strategies for cervical cancer in the county of Valles Occidental: CRICERVA clinical trial.

Acera A, Rodriguez A, Trapero-Bertran M, Soteras P, Sanchez N, Bonet JM, Manresa JM, Hidalgo P, Toran P, Prieto G.

BMC Health Serv Res. 2011 Oct 19;11:278. doi: 10.1186/1472-6963-11-278.

18.

Laboratory diagnosis of human papillomavirus virus infection in female genital tract.

Dixit R, Bhavsar C, Marfatia YS.

Indian J Sex Transm Dis. 2011 Jan;32(1):50-2. doi: 10.4103/0253-7184.81257. No abstract available.

19.

The impact of liquid-based cytology in decreasing the incidence of cervical cancer.

Gibb RK, Martens MG.

Rev Obstet Gynecol. 2011;4(Suppl 1):S2-S11.

20.

A resident-led quality improvement initiative to improve obesity screening.

Laiteerapong N, Keh CE, Naylor KB, Yang VL, Vinci LM, Oyler JL, Arora VM.

Am J Med Qual. 2011 Jul-Aug;26(4):315-22. doi: 10.1177/1062860610395930. Epub 2011 Mar 29.

Supplemental Content

Support Center